Presentation is loading. Please wait.

Presentation is loading. Please wait.

DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem.

Published byClement Jenkins Modified over 8 years ago

Similar presentations

Presentation on theme: "DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem."— Presentation transcript:

1 DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem

2 Session TitleSpeakers Design and Sample Size Planning for Multiregional Clinical Trials Jim Hung; Zhaoyang Teng; Gordon Lan Strategic Quantitative Thinking: Designing a Roadmap for Innovation Jim Hung; Rima Izem; Lisa LaVange; Karen Price; Ram Tiwari, Lilly Yue; Tom Permutt Mitigating Missing Data in Clinical Trials: Moving Toward Global Behavioral Change Impacts Efficacy, Safety and Quality Carol Robertson-Plouch; Tom Permutt; Joshua Betcher Impact of Bayesian Methods in Drug Development with Focus on Comparative Effectiveness Research Brad Carlin; Ram Tiwari; Matthew Rotelli Predictive Enrichment: Design, Development Strategies, and Methodological Issues Zoran Antonijevic; Robert Beckman; Sue-Jane Wang Key Subgroup Analysis Issues in Clinical Trials David Ohlssen; Lilly Yue; Ilya Lipkovich Continued in next slide

3 Session TitleSpeakers Your Future Success as a Master’s Level Statistician: Learn from the Past of These Industry Masters Luke Hickey; Matthew Downs; Kristine Broglio; Barbara Day Seeing is Believing! Good Graphic Design Principles for Medical Research Susan Duke; Brenda Crowe; Richard Forshee Separating Perceptions from Reality in Regards to the Acceptance of Adaptive Trials by Regulatory Agencies Lisa LaVange; Silke Jorgens; Vladimir Dragalin Exploring Bayesian Approaches Applied to New Treatments for Rare Diseases John Troiani; Scott Berry; Kit Roes Benefit/Risk Evaluation in Drug Development George Quartey; Andreas Sashegyi; Qi Jiang Pediatrics Trials: Improvements through Bayesian methods, Adaptive Design, and Modeling/Simulation Scott Berry; Freda Cooner; Brenda Cirincione Moving Beyond the Traditional Psychometric Validation of New Phase 3 Clinical Outcome Assessments Rima Izem; Cheryl Coon; Laura Lee Johnson

Download ppt "DIA Annual Meeting 2014 Statistical Science and Quantitative Thinking Track AJ Sankoh, Rima Izem."

Similar presentations

Patient Selection Markers in Drug Development Programs

Patient Selection Markers in Drug Development Programs
Delete these guides from slide master before printing or giving to the client 1 Bayesian Trial Design – Case studies Panelists Andrew Mugglin, Medtronic.

Delete these guides from slide master before printing or giving to the client 1 Bayesian Trial Design – Case studies Panelists Andrew Mugglin, Medtronic.
1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.

FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.
Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.

Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.
Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.

Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.
The Statisticians Role in Pharmaceutical Development

The Statisticians Role in Pharmaceutical Development
Industry/FDA/Academia Safety Graphics Working Group Introduction and Overview FDA/QSPI Biostatistics, Statistical Programming, and Data Management Summit.

Industry/FDA/Academia Safety Graphics Working Group Introduction and Overview FDA/QSPI Biostatistics, Statistical Programming, and Data Management Summit.
Impact of Dose Selection Strategies on the Probability of Success in the Phase III Zoran Antonijevic Senior Director Strategic Development, Biostatistics.

Impact of Dose Selection Strategies on the Probability of Success in the Phase III Zoran Antonijevic Senior Director Strategic Development, Biostatistics.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.

David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.
Norisuke Kawai Clinical Statistics, Pfizer Japan Inc.

Norisuke Kawai Clinical Statistics, Pfizer Japan Inc.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Emerging Trends in Regulatory Biostatistics - What might be their impact ? Robert T. O’Neill Ph.D. Director, Office of Biostatistics Office of Translational.

Emerging Trends in Regulatory Biostatistics - What might be their impact ? Robert T. O’Neill Ph.D. Director, Office of Biostatistics Office of Translational.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.

Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.
DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS Susan S. Ellenberg, Ph.D. Department of Biostatistics and Epidemiology University of Pennsylvania.

DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS Susan S. Ellenberg, Ph.D. Department of Biostatistics and Epidemiology University of Pennsylvania.
Planning the Lifecycle of Safety Evaluation

Planning the Lifecycle of Safety Evaluation
Study Session Experimental Design. 1. Which of the following is true regarding the difference between an observational study and and an experiment? a)

Study Session Experimental Design. 1. Which of the following is true regarding the difference between an observational study and and an experiment? a)
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Similar presentations

Ads by Google